What has SMC said?
The Scottish Medicines Consortium (SMC) has accepted dupilumab used alongside corticosteroids that are applied up the nose, for the treatment of adults with severe chronic rhinosinusitis with nasal polyps (inflammation with growths blocking the nose).
SMC has accepted dupilumab for restricted use. The restriction means it can be used in patients who have had at least one surgery for chronic rhinosinusitis with nasal polyps and have a SNOT-22 score of 50 or higher. A SNOT-22 score is the score from a 22-question survey that asks about how severe a patient’s symptoms due to chronic rhinosinusitis are.
This document summarises the SMC decision and what it means for patients.
You can find more detailed information about the SMC assessment of dupilumab by looking at the SMC detailed advice document (SMC2851).
What does SMC’s decision mean for patients?
Dupilumab for use as described above is available for prescribing on the NHS in Scotland. Your healthcare professional can discuss with you if it is the right treatment for you.
You can find more information about making decisions about your treatment here: Medicines in Scotland: What’s the right treatment for me?
More about SMC’s decision
SMC’s decision takes into account a confidential discount offered by the pharmaceutical company.
How does SMC make its decision?
SMC carefully considers every new medicine to make sure it benefits patients and is likely to be a good use of NHS resources.
To do this SMC studies the following:
- Evidence from the company about how well the medicine works compared with current treatments available in Scotland, in relation to how much they will cost to buy and use to treat patients.
- Information from patient groups about the potential impact of the medicine on patients and carers.
- Advice from healthcare professionals about any benefits of the new medicine compared to current treatment, along with how the new medicine is likely to be used.
When SMC assesses a medicine it takes account of the needs of all patients in NHSScotland, not only those who may be treated with the medicine.
You can find out more about how SMC decides here: https://www.scottishmedicines.org.uk/how-we-decide/
More information and support
The organisation below can give more information and support for people with chronic rhinosinusitis and their families. SMC is not responsible for the content of any information provided by external organisations.
Fifth Sense (operating as SmellTaste)
https://www.smelltaste.org.uk
You can find out more about dupilumab (brand name: Dupixent®) in the Patient Information Leaflet (PIL) by searching for the medicine name on the Medicines and Healthcare products Regulatory Agency (MHRA) website.
https://products.mhra.gov.uk/